Axsome Therapeutics: Treating Major Depressive Disorder. Vivos Therapeutics: Improving the Treatment of Obstructive Sleep Apnea

Axsome Therapeutics Inc and Major Depressive Disorder
In a teleconference on August 20, 2021, the U.S. Food and Drug Administration (FDA) informed Axsome Therapeutics (AXSM) that its review of the new drug application (NDA) for AXS-05, for the treatment of major depressive disorder, would not be completed by the Prescription Drug User Fee Act (PDUFA

This content is for paid subscribers.
Please click here to subscribe or here to log in.